Essential Cholesterol Burner

Dr. Bobby V. Khan, M.D., Ph.D.

“We are now dealing with an epidemic worldwide problem of metabolic problems such as diabetes mellitus and high cholesterol. At the same time, we are facing a signficant concern about cardiovascular diseases such as coronary artery disease and hypertension. We have learned a lot about these disorders and we have several good therapies available. But many people are not able to take advantage of these medications for many reasons:

  • too many adverse effects
  • it’s too expensive
  • many patients just don’t want to take prescription medications. They want to do it naturally”
Click to view full article →


Clinical Study Proven:

  • Appetite Suppression up to 40%
  • LDL-C Cholesterol Reduction up to 25%
  • Increase Energy Levels
  • Better Absorption
  • 100% Natural


  • Cholesterol reduction prescription medications costs > $200 monthly and with side effects versus ALL NATURAL clinical study proven product delivered through mints.

Key Ingredients

Proprietary potent combination of select GRAS (generally recognized as safe) with powerful and unique antioxidants that are highly safe and effective:

Berberine is a plant alkaloid with a long history of medicinal use in both Ayurvedic and Chinese medicine. It is present in many plants, including Hydrastiscanadensis (goldenseal), Coptis chinensis (Coptis orgoldenthread), Berberis aquifolium (Oregon grape), Berberis vulgaris (barberry), and Berberis aristata (tree turmeric). Berberine can be found in the root, rhizome,and stem bark of the plants.

Picrorhiza Kurroa is one of the major income generating non-timber forest products found in the Nepalese Himalayas. It is one of the oldest medicinal plants traded from the Karnali zone. Known as Kutki, it is a perennial herb and is used as a substitute for Indian gentian.

Responded to a big issue: Cardiometabolic Syndrome

Total worldwide cost of managing cardiometabolic diseases now exceeds $500 billion annually.

Obesity and Diabetes Among US Adults: Growing Prevalence

Nutraceuticals in the Cardiometabolic Syndrome: Advantages

  • A profile of safety-some people do not want to take “drugs” but are willing to take nutritional supplements
  • These agents may enhance the effect of ongoing medical therapy
  • There is potential for significant lifestyle enhancement

Essential Cholesterol Burner in the Cardiometabolic Syndrome: The Potential Market

  • One third of the U.S. population has aspects of the cardiometabolic syndrome
  • The worldwide market is $80 billion per year with projections to exceed $200 billion by end of decade
  • The Consumer Wants:
    • Clinical and scientific data
    • Safety profile
    • Natural alternative to Rx drugs
    • Belief in an effective solution

The Essential Cholesterol Burner Study

  • Performed at a highly acclaimed clinical research center in Atlanta, Georgia — with a large cardiometabolic population at different socio-economic levels
  • Study listed on clinical
  • Background: Multiple activation is significant in the management and treatment of cardiovascular disease in all patients

Targeted Population for Recruitment into the Essential Cholesterol Burner Trial

  • Men or women of any racial background, age ≥25 years
  • At risk for cardiometabolic diseases
  • Could be on existing antihypertensive, antidiabetic, or lipid lowering therapy

The Essential Cholesterol Burner Study Protocol and Timeline

  • This was a placebo-controlled, randomized, double blind study.
  • Subjects were given Compound A and Compound B, (or corresponding placebo) to be taken three times per day before meals. Treatment period was for 12 weeks.
  • Dietary counseling was given to all patients

The Essential Cholesterol Burner Study: Endpoints


  • Effect on overall appetite


  • Effect on parameters of body fat
  • Effect on metabolic profile (lipids, glucose)
  • Effect on serum biomarkers
  • Effect on blood pressure

Demographics and Metabolic Parameters of the Study Population

Women, % 61.5
Age, y 50.0 + 12.5
SBP, mm Hg 146.6 + 15.3
DBP, mm Hg 91.1 + 9.7
Waist circumference (cm) 108.4 + 15.8
Total cholesterol, mg/dL 226.6 + 39.9
LDL cholesterol, mg/dL 154.5 + 35.5
HDL cholesterol, mg/dL 43.0 + 10.0
Triglycerides, mg/dL 198.3 + 40.5
Glucose, mg/dL 105.7 + 17.3

Essential Cholesterol Burner is an Effective Appetite Suppressant

Effects on Parameters of Appetite Suppression

In the questionnaire — after 12 weeks of therapy

Placebo Essential Cholesterol Burner
Yes Yes
1. Reduced hunger between meals 42% 96%
2. Feeling more energetic 57% 96%
3. Eating less at mealtime 42% 100%

Effects on Parameters of Body Fat

Placebo Essential Cholesterol Burner
Baseline 12 weeks Baseline 12 weeks
Waist Circumference (cm)
Male 117 ± 27 121 ± 24 120 ± 20 111 ± 21 p = 0.082
Female 108 ± 24 103 ± 19 110 ± 17 105 ± 20 p = 0.114
Total body fat (percentage)
Male 39.1 ± 6.6 39.2 ± 7.0 38.1 ± 5.5 35.3 ± 5.5 p = 0.077
Female 42.2 ± 7.3 41.8 ± 6.5 42.8 ± 7.0 40.0 ± 6.1 p = 0.098

Effect of Essential Cholesterol Burner on LDL Cholesterol Levels

Effect of Essential Cholesterol Burner on Systolic Blood Pressure and Diastolic Blood Pressure

Effect on Biomarkers of Vascular Function

Measurement of serum biomarkers

Placebo Essential Cholesterol Burner
Baseline 12 weeks Baseline 12 weeks
Markers of inflammation
PAI-1 (mg/ml) 257 ± 47 236 ± 39 271 ± 35 189 ± 29 *
hsCRP (mg/l) 2.1 ± 0.3 2.1 ± 0.4 2.4 ± 0.4 1.8 ± 0.3
Markers of diabetes and insulin resistance
Glutathione redox ratio 3.0 ± 0.5 3.2 ± 0.4 3.1 ± 0.5 2.6 ± 0.4 *
HOMA-IR (index) 2.3 ± 0.4 2.0 ± 0.4 * 2.3 ± 0.3 1.5 ± 0.3 *
Direct measurement of vascular function
Endothelial FMD 4.4 ± 0.7 4.8 ± 0.4 4.3 ± 0.8 9.5 ± 0.7 *

* — value differs (p < 0.05) from baseline and placebo/12 weeks (time and group comparison)

The Essential Cholesterol Burner Study: Primary and Other Endpoints

Tolerability and Safety Profile of Essential Cholesterol Burner

Essential Cholesterol Burner was shown to be very safe and well tolerated in the study population.

  • Started Study — 42
  • Completed Study — 28 (66.7%)
  • Reasons Why Subjects Did Not Complete Study:
    • Did not want to continue — 11/14 (no adverse effects)
    • GI Symptoms — 2/14
    • Diffuse rash, moderate — 1/14

No adverse effects on liver function
No adverse effects on renal function

The Essential Cholesterol Burner Study Summary

  • Essential Cholesterol Burner was well tolerated throughout the study.
  • Essential Cholesterol Burner met the primary endpoint (suppression of appetite and parameters of weight and diet) and several secondary endpoints.
  • A rigorous protocol was followed—utilizing maximal dosage of pharmaceutical management as indicated.
  • This is a high risk population of patients—and the efficacy of Essential Cholesterol Burner was significant.

The Essential Cholesterol Burner Study CONCLUSIONS

These findings indicate that Essential Cholesterol Burner is a safe and effective agent in impacting individuals who are at risk for:

  • Diabetes mellitus
  • Hypertension
  • Dyslipidemia (all of these are serious indicators of cardio and renovascular diseases)

Essential Cholesterol Burner can be used as adjunctive management or primary management for individuals who are unable or unwilling to take pharmaceutical drugs.

Essential Cholesterol Burner — Proposed Mechanism of Actions

  • PDE inhibition
  • AMPK activation
  • Regulation of oxidative stress through Quinone Oxidoreductase 2 (QR2) inhibition
  • HMG CoA Reductase modulation

Essential Cholesterol Burner — Summary of Health Benefits

  • Addresses all components of metabolic syndrome.
  • Optimizes your lipid metabolism, including Total Cholesterol, LDL Cholesterol, HDL Cholesterol, and Triglycerides, naturally.
  • Demonstrates substantial benefits in maintaining healthy blood sugar levels.
  • Promotes liver health and fatty liver management.
  • Supports in the management of appetite suppression and weight management.

This statement has not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.